Candriam Luxembourg S.C.A. raised its position in Selecta Biosciences, Inc. (NASDAQ:SELB) by 13.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 143,000 shares of the company’s stock after purchasing an additional 17,000 shares during the quarter. Candriam Luxembourg S.C.A. owned 0.65% of Selecta Biosciences worth $2,610,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of SELB. Bank of New York Mellon Corp purchased a new stake in Selecta Biosciences in the 1st quarter worth about $211,000. UBS Group AG increased its position in shares of Selecta Biosciences by 1,215.9% during the first quarter. UBS Group AG now owns 71,361 shares of the company’s stock worth $1,022,000 after acquiring an additional 65,938 shares during the period. Goldman Sachs Group Inc. increased its holdings in Selecta Biosciences by 83.1% during the first quarter. Goldman Sachs Group Inc. now owns 31,588 shares of the company’s stock valued at $452,000 after buying an additional 14,332 shares during the period. Hamilton Lane Advisors LLC increased its holdings in Selecta Biosciences by 21.8% during the second quarter. Hamilton Lane Advisors LLC now owns 91,125 shares of the company’s stock valued at $1,810,000 after buying an additional 16,292 shares during the period. Finally, Trexquant Investment LP purchased a new position in Selecta Biosciences during the second quarter valued at approximately $334,000. 53.03% of the stock is currently owned by institutional investors.
Several equities research analysts have weighed in on the stock. Canaccord Genuity set a $25.00 target price on shares of Selecta Biosciences and gave the company a “buy” rating in a research note on Friday, August 11th. UBS AG downgraded shares of Selecta Biosciences from a “buy” rating to a “neutral” rating in a research note on Thursday, November 9th. Zacks Investment Research upgraded shares of Selecta Biosciences from a “sell” rating to a “hold” rating in a research note on Thursday, October 12th. Finally, ValuEngine downgraded shares of Selecta Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, September 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. Selecta Biosciences presently has a consensus rating of “Buy” and a consensus target price of $25.20.
In related news, insider Werner Cautreels bought 20,000 shares of the business’s stock in a transaction dated Monday, November 13th. The stock was acquired at an average price of $9.31 per share, with a total value of $186,200.00. Following the completion of the purchase, the insider now directly owns 321,203 shares of the company’s stock, valued at $2,990,399.93. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Timothy C. Barabe bought 5,000 shares of the business’s stock in a transaction dated Friday, November 10th. The shares were bought at an average cost of $9.37 per share, with a total value of $46,850.00. Following the purchase, the director now directly owns 4,992 shares of the company’s stock, valued at $46,775.04. The disclosure for this purchase can be found here. Insiders have sold 355,658 shares of company stock valued at $6,955,732 in the last three months. Corporate insiders own 41.90% of the company’s stock.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.
Receive News & Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.